Cat.NO.:A284426 Purity:98+%
Product Details of Daclatasvir 2HCl
| CAS No. : | 1009119-65-6 |
| Formula : |
C40H52Cl2N8O6 |
| M.W : |
811.80
|
| SMILES Code : | O=C([C@@H](NC(OC)=O)C(C)C)N1[C@@H](CCC1)C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O.Cl.Cl |
| Synonyms : |
BMS-790052 dihydrochloride; EBP 883 dihydrochloride; Daclatasvir dihydrochloride
|
| MDL No. : | MFCD25541736 |
| InChI Key : | BVZLLUDATICXCI-JMSCDMLISA-N |
| Pubchem ID : | 25154713 |
Safety of Daclatasvir 2HCl
| GHS Pictogram: |  |
| Signal Word: | Warning |
| Hazard Statements: | H302-H317 |
| Precautionary Statements: | P280 |
Isoform Comparison
Biological Activity
In Vitro:
| Concentration | Treated Time | Description | References |
| Huh7.5.1 cells | 10 μM | 2 hours | To evaluate the inhibitory effect of Daclatasvir on HCV infection | PMC7677215 |
| Huh7.5.1 cells | 10 μM | 48 hours | To evaluate the inhibitory effect of Daclatasvir on HCV infection, results showed significant reduction in viral RNA levels. | PMC6420960 |
| RDEB fibroblasts | 1 µM | 48 hours | To investigate the effect of Daclatasvir on the TGF-β signaling pathway, results showed that Daclatasvir inhibited the expression of TGF-β pathway targets collagen I, phosphorylated AKT, and phosphorylated SMAD3. | PMC11018630 |
In Vivo:
| Administration | Dosage | Frequency | Description | References |
| humanized chimeric mice | HCV genotype 1b, 2a or 3 infection model | oral | 1 and 2 mg/kg/day | once daily for 2.5 months (P301S Tau mice) or 9 months (3xTg mice) | To evaluate the efficacy of Daclatasvir monotherapy on HCV infection, results showed a decline in viral load but with emerging resistance | PMC7677215 |
| mice | Alb-uPA/SCID chimeric mice | intraperitoneal injection | 100 mg/kg | Single injection, samples taken after 48 hours | To evaluate the inhibitory effect of Daclatasvir on HCV infection in vivo, results showed significant reduction in viral titers. | PMC6420960 |
| Mice | MC38 tumor model | Intraperitoneal injection | 10 mg/kg | daily for 4 weeks | Daclatasvir significantly suppressed the growth of MC38 tumors and activated CD44+CD8+ T cells in the tumor microenvironment. | PMC11227557 |
| Mice | RDEB mouse model | Drinking water | 50 mg/kg | once daily for 4 weeks | To evaluate the preventive effect of Daclatasvir on fibrosis in RDEB mice, results showed that Daclatasvir significantly improved survival, weight gain, activity, and reduced the development of fibrosis. | PMC11018630 |
| Mice | Alb-uPA/SCID mouse model | Intraperitoneal injection | 3×10^5 cells | Single injection, lasting 4 weeks | To evaluate the in vivo inhibitory effect of Boceprevir on HCV genotype 1b and 2a, results showed that Boceprevir significantly reduced viral titers without evidence of drug resistance during the treatment period. | PMC6420960 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT03748745 | Drug Interactions | Phase 1 | Active, not recruiting | January 19, 2019 | China, Jilin
… More >> Phase I Clinical Trial Unit, The First Hospital of Jilin University Changchun, Jilin, China, 130000 Less << |
Protocol
| Bio Calculators | ||||
| Preparing Stock Solutions |  |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.23mL 0.25mL 0.12mL |
6.16mL 1.23mL 0.62mL |
12.32mL 2.46mL 1.23mL |
|
Reviews
There are no reviews yet.